2. 学历类
  3. Text 3 In 2010,a federal judge shook Ame

Text 3 In 2010,a federal judge shook Ame

免费题库2022-08-02  81
问题 Text 3 In 2010,a federal judge shook America's biotech industry to its core.Companies had won patents for isolated DNA for decades—by 2005 some 20%of human genes were patented.But in March 2012 a judge ruled that genes were unpatentable.Executives were violently agitated.The Biotechnology Industry Organization（BIO）,a trade group,assured members that this was just a“preliminary step”in a longer battle.On July 29th they were relieved,at least temporarily.A federal appeals court overturned the prior decision,ruling that Myriad Genetics could indeed hold patents to two genes that help forecast a woman's risk of breast cancer.The chief executive of Myriad,a company in Utah,said the ruling was a blessing to firms and patients alike.But as companies continue their attempts at personalized medicine,the courts will remain rather busy.The Myriad case itself is probably not over.Critics make three main arguments against gene patents:a gene is a product of nature,so it may not be patented;gene patents suppress innovation rather than reward it;and patents’monopolies restrict access to genetic tests such as Myriad's.A growing number seem to agree.Last year a federal taskforce urged reform for patents related to genetic tests.In October the Department of Justice filed a brief in the Myriad case,arguing that an isolated DNA molecule“is no less a product of nature…than are cotton fibres that have been separated from cotton seeds.”Despite the appeals court's decision,big questions remain unanswered.For example,it is unclear whether the sequencing of a whole genome violates the patents of individual genes within it.The case may yet reach the Supreme Court.As the industry advances,however,other suits may have an even greater impact.Companies are unlikely to file many more patents for human DNA molecules—most are unlikely patented or in the public domain.Firms are now studying how genes interact,looking for correlations that might be used to determine the causes of disease or predict a drug's efficacy.Companies are eager to win patents for“connecting the dots，”explains Hans Sauer,a lawyers for the BIO.Their success may be determined by a suit related to this issue,brought by the Mayo Clinic,which the Supreme Court will hear in its next term.The BIO recently held a convention which included sessions to coach lawyers on the shifting landscape for patents.Each meeting was packed.According to Hans Sauer,companies are eager to win patents for____A.establishing disease correlationsB.discovering gene interactionsC.drawing pictures of genesD.identifying human DNA
选项 A.establishing disease correlations
B.discovering gene interactions
C.drawing pictures of genes
D.identifying human DNA
答案 B
解析 细节题【命题思路】这是一道局部细节题，需要根据题干关键词对文章相应内容进行准确定位从而得出答案。【直击答案】根据题干的关键信息“Hans Sauer”定位到第五段末句，提到公司渴望获得专利的目的是“connecting the dots”。汉斯所说的这句话是对前一句话的总结归纳，即：公司现在正在研究基因是如何相互作用，由此寻找基因之间的相互关系，这些关系可能用于判断疾病的原因或预测药物的疗效，这就与汉斯提到的“connecting the dots”意思相呼应，故B项为正确选项。【干扰排除】A项干扰性最强，文中提到的correlations并不是指“疾病”之间的关系。C项属于无中生有，原文提及公司获得专利是为了建立疾病的联系从而治疗疾病，但是并没有信息表明公司绘画基因图。D项信息“DNA”在原文有所提及，但是原文谈到的是公司不可能申请更多的人类DNA分子的专利，并非选项中所说的识别人类DNA。
转载请注明原文地址:https://www.tihaiku.com/xueli/2699885.html
本试题收录于： 英语二研究生题库研究生入学分类

英语二研究生

研究生入学

相关试题推荐
随机试题
最新回复(0)